For example, Phase II/III trials combining paclitaxel with olaparib in patients with advanced gastric cancers, where ATM-status was stratified by immunohistochemical assessment, revealed conflicting results regarding overall survival [57]. The gene discussed is ATM; the disease is gastric cancer.